Showing 1281-1290 of 1319 results for "".
- Diazepam Nasal Spray is Commercially Available for Seizure Treatmenthttps://practicalneurology.com/news/diazepam-nasal-spray-is-commercially-available-for-seizure-treatment/2469176/Diazepam nasal spray (Valtoco; Neurelis, San Diego, CA) is now commercially available. The Food and Drug Administration (FDA) approved diazepam nasal spray for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity in January 2020. "We understa
- FDA Approves Diazepam Nasal Spray For Acute Treatment of Seizure Clustershttps://practicalneurology.com/news/fda-approves-diazepam-nasal-spray-for-acute-treatment-of-seizure-clusters/2469129/The Food and Drug Administration (FDA) has approved a diazepam nasal spray (Valtoco; Neurelis, San Diego, CA) as an acute treatment of intermittent stereotypic episodes of frequent seizure activity. The treatment is indicated for seizure clusters and acute repetit
- More Sites Offer Free Parkinson Disease Genetic Testing and Counselinghttps://practicalneurology.com/news/more-sites-offer-free-parkinson-disease-genetic-testing-and-counseling/2469122/The Parkinson's Foundation has added 5 new sites for PD GENEration: Mapping the Future of Parkinson's Disease, a first-of-its-kind national initiative that offers free genetic testing and counseling for clinically relevant Parkinson disease (PD)-related genes. The new sites include Massac
- Study Shows Obesity May be an Early Sign of Dementia And Not a Causehttps://practicalneurology.com/news/study-shows-obesity-may-be-an-early-sign-of-dementia-and-not-a-cause/2469115/A large study has found that obesity in midlife is linked to a greater risk of dementia later in life; however, poor diet and lack of exercise are not. The study is published in the December 18, 2019, online issue of
- First-In-Human Study Results Show PTI-125, An Investigational Agent, Reduces Biomarkers of Alzheimer’s Disease, Inflammation, and Neurodegenerationhttps://practicalneurology.com/news/first-in-human-study-results-show-pti-125-a-investigational-agent-reduces-biomarkers-of-alzheimers-disease-inflammation-and-neurodegeneration/2469106/At the Clinical Trials in Alzheimer Disease meeting in San Diego, CA December 4-7, 2019, results of an open label first-in-human clinical trial (NCT03748706) of PTI-125 (Cassava Sciences, Austin, TX) were presented. An investigati
- Detailed Results of Phase 3 Trials of Aducanumab for Alzheimer’s Disease Presentedhttps://practicalneurology.com/news/detailed-results-of-phase-3-trials-of-aducanumab-for-alzheimers-disease-presented/2469092/At the 12th Clinical Trials in Alzheimer’s Disease conference in San Diego, CA, detailed data from the EMERGE (NCT02484547) and ENGAGE (NCT02477800)clinical trials of
- Pimavanserin Also Effective as Adjunct Treatment for Major Depressive Disorderhttps://practicalneurology.com/news/pimavanserin-also-effective-as-adjunct-treatment-for-major-depressive-disorder/2469034/Approved for treatment of psychosis in Parkinson’s disease (PD) and with positive clinical trial results for treatment of psychosis in other forms of dementia, pimavanserin (Nuplazid; Acadia, Pharmaceuticals, San Diego, CA) may also be effective as adjunctive treatment for major depressive
- Sleep and Behavior a Growing Part of Alzheimer's Disease Researchhttps://practicalneurology.com/news/sleep-and-behavior-a-growing-part-of-alzheimers-disease-research/2469006/A new report from Elsevier Analytical Services (Philadelphia, PA) shows that sleep and behavior have become important topics within research for Alzheimer's disease (AD). The study shows that scientists who explore the connection between sleep and AD are developing new theories on the early w
- Investigational MS Treatment Diroximel Fumarate Has Improved Gastrointestinal Tolerabilityhttps://practicalneurology.com/news/investigational-ms-treatment-diroximel-fumarate-has-improved-gastrointestinal-tolerability/2468982/Topline results from the EVOLVE-MS-2 study (NCT02634307), of diroximel fumarate (ALKS8700, BIIB098; Alkermes, Waltham, MA and Biogen, Cambridge, MA) for treatment of relapsing-remitting multiple sclerosis (RRMS) have been announced. Pa
- Clinical Trials Begin for PU-AD--Potential Alzheimer’s Therapy With New Targethttps://practicalneurology.com/news/clinical-trials-begin-for-pu-ad-potential-alzheimers-therapy-with-new-target/2468978/The Food and Drug Administraion (FDA) has cleared the new drug application for PU-AD (Samus Therapeutics, Topsfield, MA), allowing a phase 1 clinical trial to begin. An investigational agent, PU-AD is the first to target heat shock proteins (HSPs) and epichaperomes in Alzheimer's disease (AD)